This case shows that the COVID-19 may induce relatively mild symptoms and a patient can recover when early diagnosis of pneumonia was made.345 When lopinavir/ritonavir was used, we found reduced viral loads and improved clinical symptoms during the treatment. So lopinavir/ritonavir can be recommended to relatively high-risk groups of COVID-19 pneumonia (elderly patients or patients with underlying diseases) from the early stage. But we need more evidence to prove the clinical efficacy of lopinavir/ritonavir based on well controlled clinical trials.